Creators of Ivermectin Won Nobel Prize for Outstanding Results Treating HUMANS.
Obviously, these scientists would not get the Nobel Prize if Ivermectin was only for horses.
U.S govt.research finds African countries using ivermectin have much lower rates of COVID mortality. Despite its controversy in the media, researchers are reporting African countries using the drug ivermectin have much lower rates of COVID-19 mortality than countries not using the medicine. One America’s Pearson Sharp has more.\
https://pubmed.ncbi.nlm.nih.gov/34466270/
Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19
Abstract
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p
U.S govt.research finds African countries using ivermectin have much lower rates of COVID mortality. Despite its controversy in the media, researchers are reporting African countries using the drug ivermectin have much lower rates of COVID-19 mortality than countries not using the medicine. One America’s Pearson Sharp has more.\
https://pubmed.ncbi.nlm.nih.gov/34466270/
Ivermectin: a multifaceted drug of Nobel prize-honored distinction with indicated efficacy against a new global scourge, COVID-19
Abstract
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p